Endo International plc Stock

Equities

ENDPQ

IE00BJ3V9050

Investment Holding Companies

Delayed OTC Markets Other stock markets 11:04:08 2024-04-26 am EDT			5-day change	1st Jan Change
0.0006 ^USD	0.00%		-14.29%	+20.00%

Mar. 22	Fourth Amended Joint Reorganization Plan Approved for Endo International plc	CI
Mar. 20	Health Care Down on Rate Bias -- Health Care Roundup	DJ

Financials (USD)

Sales 2022	2.32B	Sales 2023	2.01B	Capitalization	118K
Net income 2022	-2.92B	Net income 2023	-2.45B	EV / Sales 2022	2.97 x
Net Debt 2022	6.87B	Net Debt 2023	7.41B	EV / Sales 2023	3.68 x
P/E ratio 2022	-0.01 x	P/E ratio 2023	-	Employees	2,931
Yield 2022 *	-	Yield 2023	-	Free-Float	99.35%

More Fundamentals * Assessed data

Chart Endo International plc

Duration

Period

Style

Dynamic Chart

Latest news about Endo International plc

Fourth Amended Joint Reorganization Plan Approved for Endo International plc	Mar. 22	CI
Health Care Down on Rate Bias -- Health Care Roundup	Mar. 20	DJ
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	Mar. 20	DJ
Drugmaker Endo receives US court approval for bankruptcy restructuring	Mar. 19	RE
Drugmaker Endo receives US court approval for bankruptcy restructuring, Bloomberg News reports	Mar. 19	RE
Fourth Amended Joint Reorganization Plan Filed by Endo International plc	Mar. 18	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Health Care Flat After Trial Setbacks -- Health Care Roundup	Mar. 08	DJ
Endo International plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Endo International plc Reports Property, Plant and Equipment Impairment Charges for the Three Months Ended December 31, 2023	Mar. 06	CI
Endo International plc Provides Earnings Guidance for the Year 2024	Mar. 06	CI
Endo International plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Drugmaker Endo reaches $465 mln bankruptcy settlement with US	Feb. 29	RE
Third Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Feb. 20	CI
Motion for Exclusivity Period Extension Approved For Endo International plc	Jan. 24	CI

More news

Analyst Recommendations on Endo International plc

BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market Perform Rating	22-05-09	MT
Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight Rating	22-05-09	MT
Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $1 From $3	22-05-06	MT
Citigroup Adjusts Endo International's Price Target to $6 From $11, Reiterates Buy Rating	22-03-09	MT
BMO Capital Adjusts Endo International Price Target to $4 From $8, Maintains Market Perform Rating	22-03-03	MT

More recommendations

Press releases Endo International plc

Endo International plc - Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution	Apr. 23	AQ
Endo, Inc. Announces Proposed New Senior Secured Credit Facilities	Apr. 02	AQ
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS	Mar. 27	AQ
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution	Mar. 12	PR
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS	Mar. 06	PR

More press releases

News in other languages on Endo International plc

Endo va payer 2 milliards de dollars à cause d'un traitement opiacé	Feb. 29
Novartis conclut un accord extra-judiciaire aux Etats-Unis	22-12-29
Novartis pagará 245 millones de dólares para terminar casos antimonopolio sobre genéricos de medicamentos Exforge	22-12-28
USA-Les valeurs à suivre à Wall Street (actualisé)	22-08-17
USA-Les valeurs à suivre à Wall Street (actualisé)	22-03-25

More news

Quotes and Performance

Current month	+50.00%
1 month	+20.00%
3 months	-68.42%
6 months	-82.86%
Current year	+20.00%

More quotes

Highs and lows

1 week

0.00

1 month

0.00

Current year

0.00

0.01

1 year

0.00

0.08

3 years

0.00

7.07

5 years

0.00

10.89

10 years

0.00

96.58

More quotes

Managers and Directors - Endo International plc

Managers	Title	Age	Since
Blaise A Coleman CEO	Chief Executive Officer	50	14-12-31
Mark Bradley DFI	Director of Finance/CFO	54	06-12-31
Cheryl Stouch CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Michael Hyatt BRD	Director/Board Member	78	14-01-31
William Patrick Montague BRD	Director/Board Member	77	14-02-27
Jennifer Chao BRD	Director/Board Member	54	21-02-16

More insiders

ETFs positioned on Endo International plc

Name	Weight	AuM	1st Jan change	Investor Rating
ARMOR US EQUITY INDEX ETF - USD	0.00%	9 M€	-.--%	-

More ETFs positioned on Endo International plc

Quotes

Date	Price	Change	Volume
24-04-26	0.0006	0.00%	26 249
24-04-25	0.0006	0.00%	14,790
24-04-24	0.0006	-14.29%	6,756
24-04-22	0.0007	0.00%	39,614
24-04-19	0.0007	+16.67%	1,026

Delayed Quote OTC Markets, April 25, 2024 at 03:45 pm EDT

More quotes

Company Profile

Endo International plc has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code and is winding down its business. The Company has no business operations.

Sector

Investment Holding Companies

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Shell Companies

	1st Jan change	Capi.
ENDO INTERNATIONAL PLC	+20.00%	141K
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+119.94%	5.26B
SCREAMING EAGLE ACQUISITION CORP.	+1.60%	1.01B
CHURCHILL CAPITAL CORP VII	+2.29%	983M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+27.64%	834M
ARES ACQUISITION CORPORATION II	+1.68%	663M
E7 GROUP	+2.15%	617M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+23.11%	560M

Shell Companies